SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Provectus Pharmaceuticals Inc.
PVCT 0.06490.0%1:26 PM EST
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: jm2i123 who wrote (12313)8/13/2013 11:00:17 AM
From: NTTG1 Recommendation

Recommended By
Pogeu Mahone

  Read Replies (1) of 13111
 
Allovectin was an interesting approach, but as pointed out in more posts than you can ever cut and paste, their immune strategy and PIII protocol were very dose limiting.

PVCT has been running in the opposite direction recently; maximum number of lesions treated, isolated limb perfusion, combination with biologic immune modulators...PVCT understands they are a de-bulking cytotoxic drug.

Sitting on the sideline is hardly an endorsement for PVCT
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News